Jeremy Goldhaber-Fiebert

jeremy fisch headshot

Jeremy Goldhaber-Fiebert, PhD

  • Professor, Health Policy

Encina Commons, Room 220
615 Crothers Way
Stanford, CA 94305-6006

(650) 721-2486 (voice)
(650) 723-1919 (fax)

Biography

Jeremy Goldhaber-Fiebert, PhD, is a Professor of Health Policy, a Core Faculty Member at the Center for Health Policy and the Department of Health Policy, and a Faculty Affiliate of the Stanford Center on Longevity and Stanford Center for International Development. His research focuses on complex policy decisions surrounding the prevention and management of increasingly common, chronic diseases and the life course impact of exposure to their risk factors. In the context of both developing and developed countries including the US, India, China, and South Africa, he has examined chronic conditions including type 2 diabetes and cardiovascular diseases, human papillomavirus and cervical cancer, tuberculosis, and hepatitis C and on risk factors including smoking, physical activity, obesity, malnutrition, and other diseases themselves. He combines simulation modeling methods and cost-effectiveness analyses with econometric approaches and behavioral economic studies to address these issues. Dr. Goldhaber-Fiebert graduated magna cum laude from Harvard College in 1997, with an A.B. in the History and Literature of America. After working as a software engineer and consultant, he conducted a year-long public health research program in Costa Rica with his wife in 2001. Winner of the Lee B. Lusted Prize for Outstanding Student Research from the Society for Medical Decision Making in 2006 and in 2008, he completed his PhD in Health Policy concentrating in Decision Science at Harvard University in 2008. He was elected as a Trustee of the Society for Medical Decision Making in 2011.

Past and current research topics:

  1. Type 2 diabetes and cardiovascular risk factors: Randomized and observational studies in Costa Rica examining the impact of community-based lifestyle interventions and the relationship of gender, risk factors, and care utilization.
  2. Cervical cancer: Model-based cost-effectiveness analyses and costing methods studies that examine policy issues relating to cervical cancer screening and human papillomavirus vaccination in countries including the United States, Brazil, India, Kenya, Peru, South Africa, Tanzania, and Thailand.
  3. Measles, haemophilus influenzae type b, and other childhood infectious diseases: Longitudinal regression analyses of country-level data from middle and upper income countries that examine the link between vaccination, sustained reductions in mortality, and evidence of herd immunity.
  4. Patient adherence: Studies in both developing and developed countries of the costs and effectiveness of measures to increase successful adherence. Adherence to cervical cancer screening as well as to disease management programs targeting depression and obesity is examined from both a decision-analytic and a behavioral economics perspective.
  5. Simulation modeling methods: Research examining model calibration and validation, the appropriate representation of uncertainty in projected outcomes, the use of models to examine plausible counterfactuals at the biological and epidemiological level, and the reflection of population and spatial heterogeneity.

publications

Working Papers
October 2023

Effects of Mitigation and Control Policies in Realistic Epidemic Models Accounting for Household Transmission Dynamics

Author(s)
cover link Effects of Mitigation and Control Policies in Realistic Epidemic Models Accounting for Household Transmission Dynamics
Working Papers
June 2014

Will Divestment from Employment-Based Health Insurance Save Employers Money? The Case of State and Local Governments

Author(s)
cover link Will Divestment from Employment-Based Health Insurance Save Employers Money? The Case of State and Local Governments

In The News

Opioid Clinic
News

Are Relaxed Telehealth and Take-Home Medication Regulations for Treating Opioid Use Disorder Cost-Effective?

A multidisciplinary team of Stanford researchers has found that relaxed guidelines for opioid use disorder during the COVID-19 pandemic were likely not only effective, but cost-effective as well.
cover link Are Relaxed Telehealth and Take-Home Medication Regulations for Treating Opioid Use Disorder Cost-Effective?
Getty Images Kidneys Illustration
News

Screening Adults 35 and Older for Chronic Kidney Disease Would Increase Life Expectancy in Cost-effective Way

Many people don’t know they have chronic kidney disease until it progresses. A new study led by Stanford Health Policy researchers finds that screening would increase life expectancy in a cost-effective way.
cover link Screening Adults 35 and Older for Chronic Kidney Disease Would Increase Life Expectancy in Cost-effective Way
Jeremy Goldhaber-Fiebert Stanford Health Policy
News

Jeremy Goldhaber-Fiebert Appointed to PCORI Methodology Committee

The Patient-Centered Outcomes Research Institute is an independent, nonprofit research organization that seeks to empower patients with actionable information about their health and health-care choices.
cover link Jeremy Goldhaber-Fiebert Appointed to PCORI Methodology Committee